Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05245695 |
Recruitment Status :
Recruiting
First Posted : February 18, 2022
Last Update Posted : September 26, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Endometriosis | Other: Observational study, no intervention |
The objective is to confirm the clinical performance (sensitivity and specificity) of EndoCheck when compared to laparoscopic surgical assessment as an "aid in diagnosis" for endometriosis in subjects who present with chronic pelvic pain.
The primary endpoint of the study is to optimize the test to achieve the success criteria of at least 94% and 79% sensitivity and specificity, respectively. Secondary endpoints include examining the performance of the test in patients stratified by pain severity and other clinical factors.
Study Type : | Observational |
Estimated Enrollment : | 600 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Deep Neural Network Stratification for the Use in Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) |
Actual Study Start Date : | July 12, 2022 |
Estimated Primary Completion Date : | July 31, 2024 |
Estimated Study Completion Date : | July 31, 2024 |

- Other: Observational study, no intervention
Observational study, no intervention
- Sensitivity and Specificity [ Time Frame: 24 months ]The primary endpoint of the study is to optimize the test to achieve the success criteria of at least 94% and 79% sensitivity and specificity, respectively
- Performance [ Time Frame: 24 months ]Examining the performance of the test in patients stratified by pain severity and other clinical factors.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 14 Years to 50 Years (Child, Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Participant is willing and able to provide written informed consent.
- Participant is a female aged 14 to 50 years old at time of consent.
- Participant is scheduled to undergo laparotomy or laparoscopy secondary to chronic pain associated with suspected endometriosis.
Exclusion Criteria:
- Participant has a history of surgically determined diagnosis of endometriosis (either via visual inspection or histopathology).
- Participant is a female in a pre-menarchal state.
- Participant is pregnant.
- Participant has an active malignancy.
- Participant is known to have tested positive for human immunodeficiency virus or hepatitis A, B, or C.
- Participant has an active pelvic infection or other infections contraindicated for surgery.
- Participant has participated (±3 months of study enrollment) in a clinical trial where an investigational drug/ device/ procedure was or is planned to be administered.
- Participant has any general health or behavioral condition that, in the opinion of the investigator, should exclude the participant from participation.
- Participant is under 14 years old or over 50 years old

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05245695
Contact: Silvana Franco | 2033470151 | sfranco@aspirawh.com | |
Contact: Kayla Nolan | knolan@aspirawh.com |
United States, Arizona | |
New Horizons Clinical Trials | Recruiting |
Chandler, Arizona, United States, 852224 | |
Contact: Saira Flores, MD | |
Contact (480) 496-2236 | |
Principal Investigator: Monte Swarup | |
Arizona Gynecology Consultants | Recruiting |
Mesa, Arizona, United States, 85203 | |
Contact: Kristina Calligan kcalligan@azgyn.com | |
Principal Investigator: Kelly Roy, MD | |
United States, Delaware | |
Reproductive Associates of Delaware (RAD) | Recruiting |
Newark, Delaware, United States, 19713 | |
Contact: Eileen Davies | |
Principal Investigator: Ronald Feinberg | |
United States, Georgia | |
Midtown OBGYN North | Recruiting |
Columbus, Georgia, United States, 31909 | |
Contact: Rebecca Watkins rebeccaw@midtownob.com | |
Principal Investigator: Serena Tidwell | |
United States, Indiana | |
Axia | Recruiting |
Greenwood, Indiana, United States, 46143 | |
Contact: Amanda Schulz amanda.schulz@axiawh.com | |
Principal Investigator: Gerard Reilly, MD | |
United States, New York | |
Nezhat Surgery for Gynecology/Oncology | Recruiting |
Valley Stream, New York, United States, 11581 | |
Contact: Esra Demirel esra@farrnezhatmd.com | |
Principal Investigator: Farr Nezhat, MD | |
United States, Ohio | |
Axia Women's Health | Recruiting |
Cincinnati, Ohio, United States, 45242 | |
Contact: Brigette Tillman | |
Principal Investigator: Gerard Reilly | |
United States, Pennsylvania | |
May Grant | Recruiting |
Lancaster, Pennsylvania, United States, 17601 | |
Contact: Jillian Justice | |
Principal Investigator: Kent Meldrum | |
United States, Virginia | |
Womens Health Services of Central Virginia | Recruiting |
Lynchburg, Virginia, United States, 24502 | |
Contact: Whittney Critchley 434-485-7059 | |
Principal Investigator: Wade Neiman |
Principal Investigator: | Todd Pappas, PhD | Aspira Women's Health |
Responsible Party: | Aspira Women's Health |
ClinicalTrials.gov Identifier: | NCT05245695 |
Other Study ID Numbers: |
12-2021 |
First Posted: | February 18, 2022 Key Record Dates |
Last Update Posted: | September 26, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Endometriosis Biomarkers Deep neural network |
Endometriosis Pelvic Pain Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |
Urogenital Diseases Genital Diseases Pain Neurologic Manifestations |